share_log

科濟藥業-B：股東週年大會適用之經修訂代表委任表格

CARSGEN-B: REVISED FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING

Hong Kong Stock Exchange ·  Apr 30 10:03
Summary by Moomoo AI
科济药业-B（CARsgen Therapeutics Holdings Limited）將於2024年5月21日在中國上海市召開股東週年大會。會議將審議包括採納2023年度經審核財務報表、董事及核數師報告，以及重選董事成員等共12項普通決議案和1項特別決議案。此外，會議還將授權董事會配發、發行及處置額外股份，並購回公司股份。股東可委任代表出席會議並投票，而委任表格需於2024年5月19日前送達香港證券登記處方為有效。
科济药业-B（CARsgen Therapeutics Holdings Limited）將於2024年5月21日在中國上海市召開股東週年大會。會議將審議包括採納2023年度經審核財務報表、董事及核數師報告，以及重選董事成員等共12項普通決議案和1項特別決議案。此外，會議還將授權董事會配發、發行及處置額外股份，並購回公司股份。股東可委任代表出席會議並投票，而委任表格需於2024年5月19日前送達香港證券登記處方為有效。
CarsGen Therapeutics Holdings Limited will hold its Annual General Meeting in Shanghai, China on May 21, 2024. The meeting will include the adoption of the 2023 audited financial statements, the Directors' and Auditors' reports, and the re-election of the Board members of 12 Ordinary Resolutions and 1 Special Resolution. In addition, the meeting will authorize the Board of Directors to distribute, issue and dispose of additional shares and to repurchase the Company's shares. Shareholders may appoint representatives to attend the meeting and vote, and the nomination form must be submitted by 19 May 2024 with a prescription for registration of Hong Kong Securities to be valid.
CarsGen Therapeutics Holdings Limited will hold its Annual General Meeting in Shanghai, China on May 21, 2024. The meeting will include the adoption of the 2023 audited financial statements, the Directors' and Auditors' reports, and the re-election of the Board members of 12 Ordinary Resolutions and 1 Special Resolution. In addition, the meeting will authorize the Board of Directors to distribute, issue and dispose of additional shares and to repurchase the Company's shares. Shareholders may appoint representatives to attend the meeting and vote, and the nomination form must be submitted by 19 May 2024 with a prescription for registration of Hong Kong Securities to be valid.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more